views
New York: Pharmaceutical company Pfizer has said it was blocking use of its drugs in lethal injections, which means all federally-approved drugmakers whose medications could be used for executions have now put them off limits.
"Pfizer makes its products to enhance and save the lives of the patients we serve. Consistent with these values, Pfizer strongly objects to the use of its products as lethal injections for capital punishment," the company said in the statement made public on its website on Saturday.
Hospira had previously prohibited the use of its drugs in capital punishment, as have several other drugmakers.
Pfizer shares closed even on Friday at USD 33.19. The development means the approximately 25 FDA-approved companies worldwide able to manufacture drugs used in executions have now blocked the use of the drugs, according to Reprieve, a New York-based human rights organization opposed to the death penalty.
"Pfizer's actions cement the pharmaceutical industry's opposition to the misuse of medicines," Maya Foa, Reprieve director, said in a statement. Pfizer's announcement was unlikely to have much effect on executions, which have slowed in recent years as drugmakers' prohibition on the drugs took effect.
However, as recently as 2015, records showed that labels of Arkansas execution drugs appeared to indicate that the state's potassium chloride, which stops the heart, was made by Hospira.
Pfizer spokeswoman Rachel Hooper said the company couldn't speculate on the impact of its decision. Ohio, which last executed an inmate in January 2014, has repeatedly pushed back executions while it looks for drugs. It now has more than two dozen inmates with firm execution dates, but no drugs to put prisoners to death with.
Some remaining death penalty states have been using compounded versions of drugs that fall outside of FDA approval.
Texas, with the country's busiest death chamber, obtains its pentobarbital for lethal injections from a supplier the state identifies only as a licensed compounding pharmacy. A law that took effect in 2015 keeps the identity of the drug provider confidential.
Comments
0 comment